Open Orphan PLC 2020 Annual Report and 2021 AGM Notice (5555D)
30 June 2021 - 4:00PM
UK Regulatory
TIDMORPH
RNS Number : 5555D
Open Orphan PLC
30 June 2021
Open Orphan plc
("Open Orphan", the "Company")
2020 Annual Report and 2021 AGM Notice
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
pharmaceutical services clinical research organisation (CRO) and a
world leader in vaccine and antiviral testing using human challenge
clinical trials , announces that the following documents have been
sent to shareholders:
-- Annual Report and Accounts for the year ended 31 December 2020 ("2020 Annual Report")
-- Notice of Annual General Meeting ("AGM") 2021 and voting proxy form
In accordance with AIM Rule 26, these documents are also
available to view on the Company's website:
https://www.openorphan.com/investors/reports-and-presentations/year/2021
.
The 2020 Annual Report, and the Notice of AGM, which includes
details of voting by proxy, have been posted to shareholders who
have not consented to receive electronic communications.
The AGM is scheduled to be held at 12 noon BST on 21 July 2021
at the offices of Arden Partners plc, 125 Old Broad St, London EC2N
1AR, and will consider the resolutions set out in the Notice of
AGM.
In light of the UK Government's response to the ongoing COVID-19
outbreak, the Company and the Executive Chairman have determined
that the Resolutions to be proposed at the AGM shall be voted on
through a poll rather than on a show of hands; and, accordingly,
shareholders are strongly encouraged to either submit their Form of
Proxy or use the CREST Proxy Voting Service, rather than attend the
meeting in person.
Interested in becoming a volunteer?
hVIVO recruits many of its volunteers for its challenge study
clinical trials through its dedicated volunteer recruitment
website, www.flucamp.com . By volunteering to take part in one of
our studies in a safe, controlled, clinical environment under
expertly supervised conditions you are playing your part to further
medical research and help increase the understanding of respiratory
illnesses.
If you are interested in being contacted and provided with
details about future COVID-19 human challenge study research,
please leave your contact details at www.UKCovidChallenge.com .
For further information, please contact:
Open Orphan plc www.openorphan.com
Cathal Friel, Executive Chairman +353 (0) 1 644 0007
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Richard Johnson
/ Oscair McGrath
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson/ Richard
Chambers
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or openorphan@walbrookpr.com
Paul McManus / Sam Allen / +44 (0)7980 541 893 / +44 (0)7748 651
Lianne Cawthorne 727 /
+44 (0)7584 391 303
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
pharmaceutical service/contract research company that is a world
leader in testing vaccines and antivirals using human challenge
clinical trials. The company provides services to Big Pharma,
biotech and government/public health organisations.
Open Orphan runs challenge studies in London from both its
19-bedroom Whitechapel quarantine clinic, opened in February 2021,
and its 24-bedroom QMB clinic which also has a highly specialised
virology and immunology laboratory on-site. Open Orphan has a
leading portfolio of eight human challenge study models for
conditions such as RSV, flu, asthma and COPD. In addition, Open
Orphan is also developing the world's first COVID-19 human
challenge study model as part of the Human Challenge Programme and
has signed a reservation contract with the UK Government for the
first three COVID-19 vaccine challenge studies.
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological and digital (wearable) biomarkers. The
Disease in Motion platform has many potential applications across a
wide variety of end users including big technology, wearables,
pharma and biotech companies. Following COVID-19 there is now a
renewed interest and investment in infectious diseases.
Open Orphan's Paris office has been providing biometry, data
management and statistics to its many European pharmaceutical
clients for over 20 years. For over 15 years, the Company's
Netherlands office has been providing drug development consultancy
and services, including CMC (chemistry, manufacturing and
controls), PK and medical writing, to a broad range of European
clients. Both offices are now also fully integrated with the London
office and working on challenge study contracts as well as
supporting third party trial contracts .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSSELFAUEFSEEM
(END) Dow Jones Newswires
June 30, 2021 02:00 ET (06:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2023 to Apr 2024
